18F‐<scp>FDG PET</scp>–<scp>CT</scp> performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other?

Min, Myo; Lin, Peter; Lee, Mark; Shon, Ivan Ho; Lin, Michael; Forstner, Dion; Tieu, Minh Thi; Chicco, Andrew; Bray, Victoria; Fowler, Allan

doi:10.1111/1754-9485.12439

Cited by 19 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only three of them measured it from the combination of tumor and lymph nodes volumes. [23][24][25] A fixed SUV was the main segmentation method used to obtain the VOIs threshold, 12,[22][23][24][25][26][27][28][29][30][31] followed by a percentage of SUVmax. 20,[32][33][34][35] One study used the mediastinal blood pool 36 and another one utilized an adaptive threshold.…”

Section: Studies Characteristicsmentioning

confidence: 99%

“…21 MTV and TLG were measured alone as the main variable in seven 20,22,28,29,[31][32][33] and two 27,35 studies, respectively, and both variables were measured together in nine studies. 12,21,[23][24][25][26]30,34,36 Cut-off values were obtained through receiver operating characteristic curve (AUC-ROC), 12,21,[23][24][25][26]28,29,32,33,35,36 median values, 20,22,27 minimum P value, 34 difference between first and third tertile 31 and Q-statistic, 30 with an average of 15.38 mL for MTV and 96.21 g for TLG ( Table 3). The studies had a good quality according to NOS, as they all had a score higher than 6 ( Table 1).…”

Section: Studies Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta‐analysis

et al. 2020

View full text Add to dashboard Cite

The role of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in head and neck cancer (HNC) prognosis is not well established. We conducted a systematic review focusing on MTV and TLG measured by 18 F-FDG positron-emission tomography in HNC. Meta-analyses were developed, estimating hazard ratios (HRs) for overall survival (OS) and disease-free survival (DFS). Eighteen studies were found with a total of 1512 patients. MTVadjusted analysis had an HR of 4.65 (95% CI = 2.04-10.6) for DFS and 3.89 (95% CI = 1.47-10.30) for OS. TLG-unadjusted analysis had an HR of 3.19 (95% CI = 2.33-4.37) for DFS and 2.48 (95% CI = 1.82-3.39) for OS. TLG-adjusted analysis for DFS obtained an HR of 2.05 (95% CI = 0.96-4.39). MTV and TLG are good prognostic factors in HNC, as high values predict a worse OS and DFS. Given the important information they provide, these parameters may be considered in clinical practice, as they are easily obtainable with current technology.

show abstract

Section: Studies Characteristicsmentioning

confidence: 99%

Section: Studies Characteristicsmentioning

confidence: 99%

Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta‐analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Seven studies (374 patients) evaluated the predictive value of PET performed during RT ± CT (Brun et al, 2002;Castaldi et al, 2012;Chen et al, 2014;Farrag et al, 2010;Hentschel et al, 2011;Min et al, 2016Min et al, , 2015. All but one of them found a correlation between PET parameters RT ± CT and clinical outcome.…”

Section: Predictive Value Of Quantitative Pet Parameters During Chemomentioning

confidence: 99%

“…All but one of them found a correlation between PET parameters RT ± CT and clinical outcome. In a study by Min et al, 100 patients received a PET before and 3 weeks after the beginning of treatment (Min et al, 2016). The authors showed that pre-treatment SUVMax and mid-treatment TLG were correlated with 2-year DFS in multivariate analysis (83% vs 71.4%, p = 0.0019 and 88.4% vs 77.2%, p = 0.012, respectively).…”

Section: Predictive Value Of Quantitative Pet Parameters During Chemomentioning

confidence: 99%

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

International audience18 F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for the staging, restaging, radiotherapy planning and monitoring response in many cancers. Quantitative analyses have been introduced in order to overcome some of the limits of the visual methods, allowing an easier and more objective comparison of the inter- and intra-patients variations. The aims of this review were to report available evidences on the clinical value of quantitative PET/CT parameters in HNC. Forty-five studies, for a total of 2928 patients, were analyzed. Most of the data available dealt with the intensity of the metabolism, calculated from the Standard Uptake Value (SUV). Metabolic Tumor Volume (MTV) was well correlated with overall survival and disease free survival, with a higher predictive value than the maximum SUV. Spatial distribution of metabolism and textural analyses seems promising

show abstract

“…In contrast to dose-escalation approaches to R-ART, a separate treatment philosophy is to use interim diagnostic imaging to guide dose de-intensification in responders, with the goal to improve the acute and chronic toxicity profile of HNSCC RT. Preliminary work on correlating interim PET-CT tumor response to local-regional failure free survival (LRFS) has demonstrated that, in general, patients who have a more pronounced metabolic response by mid-treatment scan appear to have better long-term locoregional control [75][76][77]. These non-intervention studies have generated the exciting concept that interim PET-CT can select robust responders for dose de-intensification strategies, but no prospective data are yet available to prove the viability of this paradigm.…”

Section: Response-adapted Adaptive Radiotherapy (R-art)mentioning

confidence: 99%

Adaptive radiotherapy for head and neck cancer

2020

View full text Add to dashboard Cite

Background: Although there have been dramatic improvements in radiotherapy for head and neck squamous cell carcinoma (HNSCC), including robust intensity modulation and daily image guidance, these advances are not able to account for inherent structural and spatial changes that may occur during treatment. Many sources have reported volume reductions in the primary target, nodal volumes, and parotid glands over treatment, which may result in unintended dosimetric changes affecting the side effect profile and even efficacy of the treatment. Adaptive radiotherapy (ART) is an exciting treatment paradigm that has been developed to directly adjust for these changes. Main body: Adaptive radiotherapy may be divided into two categories: anatomy-adapted (A-ART) and responseadapted ART (R-ART). Anatomy-adapted ART is the process of re-planning patients based on structural and spatial changes occurring over treatment, with the intent of reducing overdosage of sensitive structures such as the parotids, improving dose homogeneity, and preserving coverage of the target. In contrast, response-adapted ART is the process of re-planning patients based on response to treatment, such that the target and/or dose changes as a function of interim imaging during treatment, with the intent of dose escalating persistent disease and/or deescalating surrounding normal tissue. The impact of R-ART on local control and toxicity outcomes is actively being investigated in several currently accruing trials. Conclusions: Anatomy-adapted ART is a promising modality to improve rates of xerostomia and coverage in individuals who experience significant volumetric changes during radiation, while R-ART is currently being studied to assess its utility in either dose escalation of radioresistant disease, or de-intensification of surrounding normal tissue following treatment response. In this paper, we will review the existing literature and recent advances regarding A-ART and R-ART.

show abstract

18F‐FDG PET–CT performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other?

Abstract: Addition of iPET significantly improves the prognostic values of all three metabolic parameters and can potentially be used in future adaptive local and systemic therapy trials.

Cited by 19 publications

References 32 publications

Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta‐analysis

Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta‐analysis

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Adaptive radiotherapy for head and neck cancer

Contact Info

Product

Resources

About